Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

11/12/24 10:34:16 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GPCR alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 STRUCTURE THERAPEUTICS INC COMMON STOCK Cusip #86366E106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #86366E106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 23,586,870 Item 6: 0 Item 7: 23,586,870 Item 8: 0 Item 9: 23,586,870 Item 11: 14.999% Item 12: HC Cusip #86366E106 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 23,586,870 Item 8: 0 Item 9: 23,586,870 Item 11: 14.999% Item 12: IN Item 1(a). Name of Issuer: STRUCTURE THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 611 GATEWAY BLVD, SUITE 223 SOUTH SAN FRANCISCO, CA 94080 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 86366E106 Item 3. Not Applicable Item 4. Ownership (a) Amount Beneficially Owned: 23,586,870 (b) Percent of Class: 14.999% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 23,586,870 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of STRUCTURE THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of STRUCTURE THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Crosby Advisors LLC N/A FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK IMPRESA MANAGEMENT LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of STRUCTURE THERAPEUTICS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $GPCR alert in real time by email

Recent Analyst Ratings for

$GPCR

Date	Price Target	Rating	Analyst
5/2/2025	$60.00	Buy	Citigroup
2/28/2025		Outperform	William Blair
1/8/2025	$50.00	Buy	Stifel
12/4/2024	$80.00	Buy	H.C. Wainwright
9/23/2024	$118.00	Overweight	Morgan Stanley
5/21/2024	$65.00	Overweight	JP Morgan
4/9/2024	$65.00	Overweight	Cantor Fitzgerald
10/19/2023	$90.00	Mkt Outperform	JMP Securities

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for
$GPCR

$GPCR
Press Releases

Fastest customizable press release news feed in the world

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

$GPCR
Financials

Live finance-specific insights

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

$GPCR
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.

$GPCR
Large Ownership Changes

This live feed shows all institutional transactions in real time.